Source - RNS
RNS Number : 1749M
Clinigen Group plc
12 October 2016

12 October 2016


Annual Report and Accounts and AGM

Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services group, announces that its annual report and accounts for the year ended 30 June 2016 is now available on the Group's website at 

Copies of the Annual Report and Accounts will be posted to shareholders later today.

The Group will hold its Annual General Meeting ('AGM') on 11 November 2016 at 10.00am at Instinctif Partners' offices, 65 Gresham Street, London EC2V 7NQ. Shaun Chilton, Group Chief Executive Officer-designate, will give a presentation at the AGM. The slides will be made available on the Group's website after the meeting. No new material information will be provided.

- Ends -


Contact Details


Clinigen Group plc

Tel: +44 (0) 1283 495010


Peter George, Group Chief Executive Officer

Shaun Chilton, Group Chief Executive Officer-designate


Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Tom Ballard (Corporate Broking)


Peel Hunt LLP - Joint Broker

Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden


Instinctif Partners


Tel: +44 (0) 20 7457 2020

Adrian Duffield / Melanie Toyne-Sewell / Jayne Crook

Email: [email protected]


About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.


The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.


Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.


The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).


Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.


For more information, please visit  

This information is provided by RNS
The company news service from the London Stock Exchange